Cellectis

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Société Anonyme
Traded as
Industry Biotechnology, genome engineering, oncology
Founded 1999
Headquarters
  • Paris XIIIème (France)
Key people
André Choulika (CEO)
Products
Website cellectis.com

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.[1] It has offices in Paris and New York City.

Cellectis was founded by André Choulika in 1999.[2] It built up a successful business based on the use of meganucleases in genome engineering. Cellectis went public in 2007, and raised €21 million in a stock offering on EuroNext. In 2010 it acquired Cyto Pulse, which had developed a new electroporation technology,[3] and in 2011 it paid €26 million for Cellartis, a Swedish biotechnology company.[2] The company employed nearly 300 people.[2]

With the advent of the CRISPR (clustered regularly interspaced short palindromic repeat) genome editing technique, the Cellectis meganuclease technology became uneconomic, and by 2013 the company was close to bankruptcy. It restructured, closed laboratories and reduced staff, and shifted research emphasis toward CAR-T technologies for cancer immunotherapy. In 2014 it reached financing deals with Servier and Pfizer.[2]

In March 2015 the company raised US$228 million through a stock offering on NASDAQ. The shares fell by 15% in the first week of trading.[4]

References[edit]

  1. ^ Bryce Elder, Arash Massoud, Andrew Ward, David Crow (28 May 2015). Biotech Cellectis in takeover talks with Pfizer. Financial Times. Accessed March 2016. (subscription required).
  2. ^ a b c d Philip Hemme (15 July 2015). "How Servier saved Cellectis, the French CAR-T Miracle". Labiotech.eu. Retrieved 16 March 2016. 
  3. ^ "Genetic Engineering & Biotechnology News - Biotech from Bench to Business". Genengnews.com. 8 November 2013. Archived from the original on 22 March 2016. Retrieved 16 March 2016. 
  4. ^ "US IPO Weekly Recap: SolarEdge shines while other IPOs fall flat". NASDAQ.com. 27 March 2015. Retrieved 18 September 2017.